Literature DB >> 20531375

Association of thymidylate synthase enhancer region polymorphisms with thymidylate synthase activity in vivo.

C E de Bock1, M B Garg, N Scott, J A Sakoff, F E Scorgie, S P Ackland, L F Lincz.   

Abstract

Two known polymorphisms in the 5' enhancer region (ER) of the thymidylate synthase (TS) gene, a variable number of tandem repeats of a 28 bp sequence (2R/3R) and a further G>C single nucleotide substitution within the repeats, result in genotypes with 0-5 functional upstream stimulatory factor (USF) E-box consensus elements. However, the relationship between these polymorphisms, regulation of TS expression and patient response to fluoropyrimidine treatment has been inconsistent. In this study, seven possible TSER allele configurations showed similar patterns of luciferase gene expression regardless of cell type or USF-1 content, with no significant difference in promoter activity between the wild-type 2RGC and 3RGGC (1.40±0.37 vs 1.43±0.32, P=0.90), whereas the minor alleles, 2RCC and 3RGCC, were significantly reduced (0.84±0.17, P=0.01) and increased (3.19±0.72, P=0.001) respectively. Patient plasma levels of 2'-deoxyuridine, a surrogate marker of TS activity, were significantly different between genotypes (P<0.001) and inversely related to luciferase activity (P=0.02) but not to the absolute number of functional repeated elements (P=0.16), suggesting that the position, rather than the number of functional USF E-box repeats in the TSER, is responsible for determining gene expression in vitro and TS activity in vivo.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20531375     DOI: 10.1038/tpj.2010.43

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  10 in total

1.  Reexamining a proposal: thymidylate synthase 5'-untranslated region as a regulator of translation efficiency.

Authors:  Soma Ghosh; Jordan M Winter; Kalpesh Patel; Scott E Kern
Journal:  Cancer Biol Ther       Date:  2011-10-15       Impact factor: 4.742

2.  Detection of the G>C SNP and rare mutations in the 28-bp repeat of TYMS using gel-based capillary electrophoresis.

Authors:  Fabienne Thomas; Janelle M Hoskins; Anne Dvorak; Benjamin R Tan; Howard L McLeod
Journal:  Pharmacogenomics       Date:  2010-12       Impact factor: 2.533

Review 3.  Germline oncopharmacogenetics, a promising field in cancer therapy.

Authors:  Chiara Pesenti; Milena Gusella; Silvia M Sirchia; Monica Miozzo
Journal:  Cell Oncol (Dordr)       Date:  2015-01-09       Impact factor: 6.730

4.  Thymidylate synthase polymorphisms and risk of conotruncal heart defects.

Authors:  Huiping Zhu; Wei Yang; Nathan Shaw; Spencer Perloff; Suzan L Carmichael; Richard H Finnell; Gary M Shaw; Edward J Lammer
Journal:  Am J Med Genet A       Date:  2012-08-07       Impact factor: 2.802

5.  Analysis of polymorphisms and haplotype structure of the human thymidylate synthase genetic region: a tool for pharmacogenetic studies.

Authors:  Soma Ghosh; M Zulfiquer Hossain; Michael Borges; Michael G Goggins; Roxann G Ingersoll; James R Eshleman; Alison P Klein; Scott E Kern
Journal:  PLoS One       Date:  2012-04-05       Impact factor: 3.240

6.  Delimiting Allelic Imbalance of TYMS by Allele-Specific Analysis.

Authors:  Emilia Balboa-Beltrán; Raquel Cruz; Angel Carracedo; Francisco Barros
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

7.  TSER polymorphism is not associated with risk of pediatric acute lymphoblastic leukemia: A meta-analysis.

Authors:  Zhaohua Qiao; Dan Lou; Li Ruan
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.889

8.  Correlation between thymidylate synthase gene polymorphisms and efficacy of pemetrexed in advanced non-small cell lung cancer.

Authors:  Qiong Hu; Xuefei Li; Chunxia Su; Xiaoxia Chen; Guanghui Gao; Jie Zhang; Yinmin Zhao; Jiayu Li; Caicun Zhou
Journal:  Exp Ther Med       Date:  2012-09-28       Impact factor: 2.447

9.  Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines.

Authors:  Barbara A Jennings; Yoon K Loke; Jane Skinner; Melanie Keane; Gavin S Chu; Richard Turner; Daniel Epurescu; Ann Barrett; Gavin Willis
Journal:  PLoS One       Date:  2013-10-22       Impact factor: 3.240

10.  Plasma deoxyuridine as a surrogate marker for toxicity and early clinical response in patients with metastatic colorectal cancer after 5-FU-based therapy in combination with arfolitixorin.

Authors:  Helena Taflin; Elisabeth Odin; Göran Carlsson; Roger Tell; Bengt Gustavsson; Yvonne Wettergren
Journal:  Cancer Chemother Pharmacol       Date:  2020-10-24       Impact factor: 3.333

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.